1
|
Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation. Microbiol Spectr 2022; 10:e0278121. [PMID: 35616371 PMCID: PMC9241896 DOI: 10.1128/spectrum.02781-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Despite a remarkable improvement in health care and continued drug discovery efforts, malaria control efforts are continuously challenged by the emergence of drug-resistant parasite strains. Given a long and risky development path of new drugs, repurposing existing drugs for the treatment of malaria is an attractive and shorter path. Tamoxifen, a selective estrogen receptor modulator (SERM) for the treatment and prevention of estrogen receptor-positive breast cancer, possesses antibacterial, antifungal, and antiparasitic activities. Hence, we assessed tamoxifen, raloxifene, and bazedoxifene, which represent the first-, second-, and third-generation SERMs, respectively, for antimalarial activity. Raloxifene and bazedoxifene inhibited the erythrocytic development of Plasmodium falciparum with submicromolar 50% inhibitory concentration (IC50) values. Among the three, bazedoxifene was the most potent and also decreased P. berghei infection in female mice but not in male mice. However, bazedoxifene similarly inhibited P. falciparum growth in erythrocytes of male and female origin, which highlights the importance of sex-specific host physiology in drug efficacy. Bazedoxifene was most potent on early ring-stage parasites, and about 35% of the treated parasites did not contain hemozoin in the food vacuole. Bazedoxifene-treated parasites had almost 34% less hemozoin content than the control parasites. However, both control and bazedoxifene-treated parasites had similar hemoglobin levels, suggesting that bazedoxifene inhibits hemozoin formation and that toxicity due to accumulation of free heme could be a mechanism of its antimalarial activity. Because bazedoxifene is in clinical use and bazedoxifene-chloroquine combination shows an additive antiparasitic effect, bazedoxifene could be an adjunctive partner of currently used antimalarial regimens. IMPORTANCE The emergence and spread of drug-resistant strains of the human malaria parasite Plasmodium falciparum has necessitated new drugs. Selective estrogen receptor modulators are in clinical use for the prevention and treatment of breast cancer and postmenopausal osteoporosis. We demonstrate that bazedoxifene, a third-generation selective estrogen receptor modulator, has potent inhibitory activity against both susceptible and drug-resistant strains of Plasmodium falciparum. It also blocked the development of Plasmodium berghei in mice. The inhibitory effect was strongest on the ring stage and resulted in the inhibition of hemozoin formation, which could be the major mechanism of bazedoxifene action. Hemozoin is a nontoxic polymer of heme, which is a by-product of hemoglobin degradation by the malaria parasite during its development within the erythrocyte. Because bazedoxifene is already in clinical use for the treatment of postmenopausal osteoporosis, our findings support repurposing of bazedoxifene as an antimalarial.
Collapse
|
2
|
Chakrabarti M, Joshi N, Kumari G, Singh P, Shoaib R, Munjal A, Kumar V, Behl A, Abid M, Garg S, Gupta S, Singh S. Interaction of Plasmodium falciparum apicortin with α- and β-tubulin is critical for parasite growth and survival. Sci Rep 2021; 11:4688. [PMID: 33633135 PMCID: PMC7907060 DOI: 10.1038/s41598-021-83513-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2020] [Accepted: 12/16/2020] [Indexed: 01/31/2023] Open
Abstract
Cytoskeletal structures of Apicomplexan parasites are important for parasite replication, motility, invasion to the host cell and survival. Apicortin, an Apicomplexan specific protein appears to be a crucial factor in maintaining stability of the parasite cytoskeletal assemblies. However, the function of apicortin, in terms of interaction with microtubules still remains elusive. Herein, we have attempted to elucidate the function of Plasmodium falciparum apicortin by monitoring its interaction with two main components of parasite microtubular structure, α-tubulin-I and β-tubulin through in silico and in vitro studies. Further, a p25 domain binding generic drug Tamoxifen (TMX), was used to disrupt PfApicortin-tubulin interactions which led to the inhibition in growth and progression of blood stage life cycle of P. falciparum.
Collapse
Affiliation(s)
- Malabika Chakrabarti
- grid.10706.300000 0004 0498 924XSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067 India
| | - Nishant Joshi
- grid.410868.30000 0004 1781 342XDepartment of Life Sciences, School of Natural Sciences, Shiv Nadar University, Gautam Budh Nagar, Noida, 201314 UP India
| | - Geeta Kumari
- grid.10706.300000 0004 0498 924XSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067 India
| | - Preeti Singh
- grid.10706.300000 0004 0498 924XSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067 India
| | - Rumaisha Shoaib
- grid.411818.50000 0004 0498 8255Medicinal Chemistry Laboratory, Department of Biosciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, 110025 India
| | - Akshay Munjal
- grid.10706.300000 0004 0498 924XSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067 India
| | - Vikash Kumar
- grid.10706.300000 0004 0498 924XSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067 India
| | - Ankita Behl
- grid.10706.300000 0004 0498 924XSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067 India
| | - Mohammad Abid
- grid.411818.50000 0004 0498 8255Medicinal Chemistry Laboratory, Department of Biosciences, Jamia Millia Islamia, Jamia Nagar, New Delhi, 110025 India
| | - Swati Garg
- grid.10706.300000 0004 0498 924XSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067 India
| | - Sonal Gupta
- grid.10706.300000 0004 0498 924XSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067 India
| | - Shailja Singh
- grid.10706.300000 0004 0498 924XSpecial Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, 110067 India ,grid.410868.30000 0004 1781 342XDepartment of Life Sciences, School of Natural Sciences, Shiv Nadar University, Gautam Budh Nagar, Noida, 201314 UP India
| |
Collapse
|
3
|
Abstract
The concept of repurposing previously approved medications to the treatment of new indications by taking advantage of off-target effects has gained traction in recent years, particularly in areas of medicine that do not offer large profits to pharmaceutical firms. As infectious disease discovery research has declined among large pharmaceutical companies, the potential payoff of repurposing has become attractive. The concept of repurposing previously approved medications to the treatment of new indications by taking advantage of off-target effects has gained traction in recent years, particularly in areas of medicine that do not offer large profits to pharmaceutical firms. As infectious disease discovery research has declined among large pharmaceutical companies, the potential payoff of repurposing has become attractive. From these efforts, the triphenylethylene class of selective estrogen receptor modulators related to tamoxifen has shown activity against a wide range of medically important human pathogens, including bacteria, fungi, parasites, and viruses. Because it has activity against many pathogens affecting people in resource-limited areas of the world, TAM and related drugs may be particularly useful. Here, we review the in vitro, in vivo, and mechanistic studies of the anti-infective activity of tamoxifen, toremifene, clomiphene, and their analogs. We also discuss the pharmacologic properties of this privileged scaffold and its potential utility in treating infectious diseases.
Collapse
|
4
|
Meier A, Erler H, Beitz E. Targeting Channels and Transporters in Protozoan Parasite Infections. Front Chem 2018; 6:88. [PMID: 29637069 PMCID: PMC5881087 DOI: 10.3389/fchem.2018.00088] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Accepted: 03/12/2018] [Indexed: 12/25/2022] Open
Abstract
Infectious diseases caused by pathogenic protozoa are among the most significant causes of death in humans. Therapeutic options are scarce and massively challenged by the emergence of resistant parasite strains. Many of the current anti-parasite drugs target soluble enzymes, generate unspecific oxidative stress, or act by an unresolved mechanism within the parasite. In recent years, collections of drug-like compounds derived from large-scale phenotypic screenings, such as the malaria or pathogen box, have been made available to researchers free of charge boosting the identification of novel promising targets. Remarkably, several of the compound hits have been found to inhibit membrane proteins at the periphery of the parasites, i.e., channels and transporters for ions and metabolites. In this review, we will focus on the progress made on targeting channels and transporters at different levels and the potential for use against infections with apicomplexan parasites mainly Plasmodium spp. (malaria) and Toxoplasma gondii (toxoplasmosis), with kinetoplastids Trypanosoma brucei (sleeping sickness), Trypanosoma cruzi (Chagas disease), and Leishmania ssp. (leishmaniasis), and the amoeba Entamoeba histolytica (amoebiasis).
Collapse
Affiliation(s)
- Anna Meier
- Department of Pharmaceutical and Medicinal Chemistry, Christian-Albrechts-University of Kiel, Kiel, Germany
| | - Holger Erler
- Department of Pharmaceutical and Medicinal Chemistry, Christian-Albrechts-University of Kiel, Kiel, Germany
| | - Eric Beitz
- Department of Pharmaceutical and Medicinal Chemistry, Christian-Albrechts-University of Kiel, Kiel, Germany
| |
Collapse
|
5
|
Transmembrane solute transport in the apicomplexan parasite Plasmodium. Emerg Top Life Sci 2017; 1:553-561. [PMID: 33525850 DOI: 10.1042/etls20170097] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2017] [Revised: 11/12/2017] [Accepted: 11/16/2017] [Indexed: 12/22/2022]
Abstract
Apicomplexa are a large group of eukaryotic, single-celled parasites, with complex life cycles that occur within a wide range of different microenvironments. They include important human pathogens such as Plasmodium, the causal agent of malaria, and Toxoplasma, which causes toxoplasmosis most often in immunocompromised individuals. Despite environmental differences in their life cycles, these parasites retain the ability to obtain nutrients, remove waste products, and control ion balances. They achieve this flexibility by relying on proteins that can deliver and remove solutes. This reliance on transport proteins for essential functions makes these pathways excellent potential targets for drug development programmes. Transport proteins are frequently key mediators of drug resistance by their ability to remove drugs from their sites of action. The study of transport processes mediated by integral membrane proteins and, in particular, identification of their physiological functions and localisation, and differentiation from host orthologues has already established new validated drug targets. Our understanding of how apicomplexan parasites have adapted to changing environmental challenges has also increased through the study of their transporters. This brief introduction to membrane transporters of apicomplexans highlights recent discoveries focusing on Plasmodium and emphasises future directions.
Collapse
|
6
|
Gomes A, Machado M, Lobo L, Nogueira F, Prudêncio M, Teixeira C, Gomes P. N-Cinnamoylation of Antimalarial Classics: Effects of Using Acyl Groups Other than Cinnamoyl toward Dual-Stage Antimalarials. ChemMedChem 2015; 10:1344-9. [PMID: 26038181 DOI: 10.1002/cmdc.201500164] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2015] [Indexed: 01/08/2023]
Abstract
In a follow-up study to our reports of N-cinnamoylated chloroquine and quinacrine analogues as promising dual-stage antimalarial leads with high in vitro potency against both blood-stage Plasmodium falciparum and liver-stage Plasmodium berghei, we decided to investigate the effect of replacing the cinnamoyl moiety with other acyl groups. Thus, a series of N-acylated analogues were synthesized, and their activities against blood- and liver-stage Plasmodium spp. were assessed along with their in vitro cytotoxicities. Although the new N-acylated analogues were found to be somewhat less active and more cytotoxic than their N-cinnamoylated counterparts, they equally displayed nanomolar activities in vitro against blood-stage drug-sensitive and drug-resistant P. falciparum, and significant in vitro liver-stage activity against P. berghei. Therefore, it is demonstrated that simple N-acylated surrogates of classical antimalarial drugs are promising dual-stage antimalarial leads.
Collapse
Affiliation(s)
- Ana Gomes
- CICECO, Departamento de Química, Universidade de Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro (Portugal)
| | - Marta Machado
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa (Portugal)
| | - Lis Lobo
- Centro de Malária e Outras Doenças Tropicais, Instituto de Higiene e Medicina Tropical, R. da Junqueira 100, 1349-008 Lisboa (Portugal)
| | - Fátima Nogueira
- Centro de Malária e Outras Doenças Tropicais, Instituto de Higiene e Medicina Tropical, R. da Junqueira 100, 1349-008 Lisboa (Portugal)
| | - Miguel Prudêncio
- Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa (Portugal)
| | - Cátia Teixeira
- CICECO, Departamento de Química, Universidade de Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro (Portugal).
| | - Paula Gomes
- UCIBIO-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, Rua do Campo Alegre 687, 4169-007 Porto (Portugal).
| |
Collapse
|
7
|
Eaton P, Zuzarte-Luis V, Mota MM, Santos NC, Prudêncio M. Infection by Plasmodium changes shape and stiffness of hepatic cells. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2012; 8:17-9. [DOI: 10.1016/j.nano.2011.10.004] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Revised: 09/27/2011] [Accepted: 10/04/2011] [Indexed: 11/28/2022]
|
8
|
Rodrigues T, Prudêncio M, Moreira R, Mota MM, Lopes F. Targeting the liver stage of malaria parasites: a yet unmet goal. J Med Chem 2011; 55:995-1012. [PMID: 22122518 DOI: 10.1021/jm201095h] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Tiago Rodrigues
- Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-019 Lisbon, Portugal
| | | | | | | | | |
Collapse
|
9
|
Prudêncio M, Mota MM, Mendes AM. A toolbox to study liver stage malaria. Trends Parasitol 2011; 27:565-74. [PMID: 22015112 DOI: 10.1016/j.pt.2011.09.004] [Citation(s) in RCA: 96] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2011] [Revised: 09/09/2011] [Accepted: 09/20/2011] [Indexed: 01/28/2023]
Abstract
The first obligatory phase of mammalian infection by Plasmodium parasites, the causative agents of malaria, occurs in the liver of the host. This stage of Plasmodium infection bears enormous potential for anti-malarial intervention. Recent technological progress has strongly contributed to overcoming some of the long-standing difficulties in experimentally assessing hepatic infection by Plasmodium. Here, we review appropriate infection models and infection assessment tools, and provide a comprehensive description of recent advances in experimental strategies to investigate the liver stage of malaria. These issues are discussed in the context of current challenges in the field to provide researchers with the technical tools that enable effective experimental approaches to study liver stage malaria.
Collapse
Affiliation(s)
- Miguel Prudêncio
- Unidade de Malária, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal.
| | | | | |
Collapse
|
10
|
Baumeister S, Wiesner J, Reichenberg A, Hintz M, Bietz S, Harb OS, Roos DS, Kordes M, Friesen J, Matuschewski K, Lingelbach K, Jomaa H, Seeber F. Fosmidomycin uptake into Plasmodium and Babesia-infected erythrocytes is facilitated by parasite-induced new permeability pathways. PLoS One 2011; 6:e19334. [PMID: 21573242 PMCID: PMC3087763 DOI: 10.1371/journal.pone.0019334] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2011] [Accepted: 03/27/2011] [Indexed: 11/18/2022] Open
Abstract
Background Highly charged compounds typically suffer from low membrane permeability and thus are generally regarded as sub-optimal drug candidates. Nonetheless, the highly charged drug fosmidomycin and its more active methyl-derivative FR900098 have proven parasiticidal activity against erythrocytic stages of the malaria parasite Plasmodium falciparum. Both compounds target the isoprenoid biosynthesis pathway present in bacteria and plastid-bearing organisms, like apicomplexan parasites. Surprisingly, the compounds are inactive against a range of apicomplexans replicating in nucleated cells, including Toxoplasma gondii. Methodology/Principal Findings Since non-infected erythrocytes are impermeable for FR90098, we hypothesized that these drugs are taken up only by erythrocytes infected with Plasmodium. We provide evidence that radiolabeled FR900098 accumulates in theses cells as a consequence of parasite-induced new properties of the host cell, which coincide with an increased permeability of the erythrocyte membrane. Babesia divergens, a related parasite that also infects human erythrocytes and is also known to induce an increase in membrane permeability, displays a similar susceptibility and uptake behavior with regard to the drug. In contrast, Toxoplasma gondii-infected cells do apparently not take up the compounds, and the drugs are inactive against the liver stages of Plasmodium berghei, a mouse malaria parasite. Conclusions/Significance Our findings provide an explanation for the observed differences in activity of fosmidomycin and FR900098 against different Apicomplexa. These results have important implications for future screens aimed at finding new and safe molecular entities active against P. falciparum and related parasites. Our data provide further evidence that parasite-induced new permeability pathways may be exploited as routes for drug delivery.
Collapse
Affiliation(s)
- Stefan Baumeister
- Parasitologie, Fachbereich Biologie, Philipps-Universität, Marburg, Germany
| | - Jochen Wiesner
- Institut für Klinische Immunologie und Transfusionsmedizin, Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany
| | - Armin Reichenberg
- Institut für Klinische Immunologie und Transfusionsmedizin, Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany
| | - Martin Hintz
- Institut für Klinische Immunologie und Transfusionsmedizin, Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany
| | - Sven Bietz
- Parasitologie, Fachbereich Biologie, Philipps-Universität, Marburg, Germany
| | - Omar S. Harb
- Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - David S. Roos
- Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
| | - Maximilian Kordes
- Parasitology Unit, Max-Planck-Institute for Infection Biology, Berlin, Germany
| | - Johannes Friesen
- Parasitology Unit, Max-Planck-Institute for Infection Biology, Berlin, Germany
| | - Kai Matuschewski
- Parasitology Unit, Max-Planck-Institute for Infection Biology, Berlin, Germany
| | - Klaus Lingelbach
- Parasitologie, Fachbereich Biologie, Philipps-Universität, Marburg, Germany
| | - Hassan Jomaa
- Institut für Klinische Immunologie und Transfusionsmedizin, Universitätsklinikum Giessen und Marburg GmbH, Giessen, Germany
| | - Frank Seeber
- Parasitologie, Fachbereich Biologie, Philipps-Universität, Marburg, Germany
- Fachgebiet 16 Parasitologie, Robert-Koch-Institut, Berlin, Germany
- * E-mail:
| |
Collapse
|
11
|
Exploiting the therapeutic potential of Plasmodium falciparum solute transporters. Trends Parasitol 2010; 26:284-96. [DOI: 10.1016/j.pt.2010.03.004] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2009] [Revised: 03/02/2010] [Accepted: 03/05/2010] [Indexed: 01/16/2023]
|